Developing anti-fibrotics for diseases of aging. Prof Darren Kelly, CEO, Fibrotech Therapeutics




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Developing anti-fibrotics for diseases of aging. Prof Darren Kelly, CEO, Fibrotech Therapeutics
Released on: May 06, 2014. © PTV
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    In this interview filmed at BIO Europe in Turin, Fintan Walton talks to Prof Darren Kelly, CEO, Fibrotech Therapeutics, who have recently been acquired by Shire plc for US$75M plus milestones.
  • Summary
  • Transcript
  • Participants
  • Company
In this interview filmed at BIO Europe in Turin, Fintan Walton talks to Prof Darren Kelly, CEO, Fibrotech Therapeutics, who have recently been acquired by Shire plc for US$75M plus milestones. Fibrotech is an Australian biopharmaceutical company developing a new class of drugs to prevent a massive health burden associated with fibrosis (tissue scarring). The Company develops novel anti-fibrotic drug candidates for the treatment of the fibrosis prevalent in such chronic conditions as chronic kidney disease, chronic heart failure, pulmonary fibrosis and arthritis. Fibrotech’s lead product FT011 is an antifibrotic to prevent the tissue fibrosis associated with diabetic nephropathy and is currently undergoing safety testing in a Phase I clinical trial. Diabetic nephropathy is the leading cause of end-stage renal disease, a severe medical condition that can only be managed with dialysis or kidney transplantation. There are several products in preclinical development selected from over 150 analogues, many of which are novel chemical entities and are markedly improved antifibrotic agents.
In this interview filmed at BIO Europe in Turin, Fintan Walton talks to Prof Darren Kelly, CEO, Fibrotech Therapeutics, who have recently been acquired by Shire plc for US$75M plus milestones. Fibrotech is an Australian biopharmaceutical company developing a new class of drugs to prevent a massive health burden associated with fibrosis (tissue scarring). The Company develops novel anti-fibrotic drug candidates for the treatment of the fibrosis prevalent in such chronic conditions as chronic kidney disease, chronic heart failure, pulmonary fibrosis and arthritis. Fibrotech’s lead product FT011 is an antifibrotic to prevent the tissue fibrosis associated with diabetic nephropathy and is currently undergoing safety testing in a Phase I clinical trial. Diabetic nephropathy is the leading cause of end-stage renal disease, a severe medical condition that can only be managed with dialysis or kidney transplantation. There are several products in preclinical development selected from over 150 analogues, many of which are novel chemical entities and are markedly improved antifibrotic agents.
Prof Darren Kelly
Fibrotech Therapeutics
FibroTech Therapeutics
Fibrotech is an Australian biopharmaceutical company developing a new class of drugs to prevent a massive health burden associated with fibrosis (tissue scarring). The Company develops novel anti-fibrotic drug candidates for the treatment of the fibrosis prevalent in such chronic conditions as chronic kidney disease, chronic heart failure, pulmonary fibrosis and arthritis. Fibrotech’s lead product FT011 is an antifibrotic to prevent the tissue fibrosis associated with diabetic nephropathy and is currently undergoing safety testing in a Phase I clinical trial. Diabetic nephropathy is the leading cause of end-stage renal disease, a severe medical condition that can only be managed with dialysis or kidney transplantation. There are several products in preclinical development selected from over 150 analogues, many of which are novel chemical entities and are markedly improved antifibrotic agents. Fibrotech was founded in 2006 and is located in Melbourne Australia.